Solutions
IntegriChain connects your finance, operations, and commercial teams on a single platform. ICyte is built for every stage of drug commercialization, from first launch to portfolio growth.
Solutions
Transforming access from strategy to operational execution
The Integrated Ecosystem Behind Smarter Market Access
Biopharmaceutical organizations don't struggle because of one problem they struggle because critical teams, data, and processes aren't connected. IntegriChain changes that. Our integrated ecosystem of technology, data, managed services, and consulting brings finance, operations, and commercial teams together, so organization can move faster, reduce risk, and get therapies to patients without the friction.
$5B+
in industry rebates processed through the ICyte platform
236 million
EDI records processed monthly
60%+
of U.S. pharmaceutical products launches supported since 2017
64%+
of Orphan and Rare Disease products launched supported since 2017
Not Sure Where to Start?
Solutions by stage
Built for Where You Are and Where You're Going
Every organization faces different challenges depending on where they are in the commercialization journey. IntegriChain's solutions are designed to meet you at your stage and grow with you.
Bringing a therapy to market for the first time is complex. IntegriChain gives emerging companies the data infrastructure, market access strategy, and operational frameworks to launch with confidence without building everything from scratch.
"Product launch experts, supported by market-tested, archetype-based launch roadmaps."
As your product matures, so do the demands on your market access team. IntegriChain helps organizations optimize GTN performance, tighten contracting controls, and maintain payer and channel visibility to protect and grow revenue over time.
"Creating a right-sized, data-driven process for tracking and improving in-line product performance."
Scaling a portfolio means multiplying complexity across contracts, data, compliance, and access strategy. IntegriChain provides the platform and expertise to manage that complexity, so expansion accelerates outcomes, not overhead.
"Trusted by more than half of the Top 50 biopharma organizations managing multi-product portfolios."